Migraine is a common, complex and certainly fascinating disorder of the brain (Lipton et al ., 2001; Goadsby et al ., 2002), which most active clinicians would agree needs more treatments (Goadsby and Sprenger, 2010). Over the last two decades we have seen substantial advances in migraine therapeutics with the development of triptans, serotonin 5-HT1B/1D receptor agonists (Ferrari et al ., 2001), gepants, calcitonin gene-related peptide (CGRP) receptor antagonists (Ho et al ., 2010), and most recently ditans, serotonin 5-HT1F receptor agonists (Ferrari et al ., 2010). Each targets, among other sites the trigeminovascular system, the trigeminal afferent innervation of the pain-producing meninges (Feindel et al ., 1960; McNaughton and Feindel, 1977) that projects to second order afferents in the trigeminocervical complex (Akerman et al ., 2011). This issue of Brain illustrates yet another target, weaving a very engaging tale of biology, herbalism and therapeutics (Nassini et al ., 2012). Nassini and colleagues (2012) studied a candidate compound, the monoterpene ketone umbellulone, a volatile component of the leaves of …